Hypertrophic obstructive cardiomyopathy: hemodynamic improvement with intravenous verapamil

S J Roth1, C B Porter, L A Latson

  • 1The Lillie Frank Abercrombie Section of Cardiology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA.

Insights

Intravenous verapamil effectively reduced left ventricular outflow tract gradients in two pediatric patients with hypertrophic obstructive cardiomyopathy when beta blockers were contraindicated. This suggests verapamil as a potential treatment for selected cases.

Area of Science:

  • Cardiology
  • Pediatric Medicine
  • Pharmacology

Background:

  • Hypertrophic obstructive cardiomyopathy (HOCM) presents a significant challenge in pediatric patients.
  • Traditional therapies like beta-adrenergic antagonists may be contraindicated or ineffective.
  • Managing left ventricular outflow tract (LVOT) gradient is crucial for patient outcomes.

Purpose of the Study:

  • To evaluate the efficacy of intravenous verapamil in reducing LVOT gradient in pediatric HOCM.
  • To explore verapamil as an alternative treatment when standard therapies are not suitable.

Main Methods:

  • Case study of two pediatric patients with HOCM.
  • Intravenous administration of verapamil.
  • Measurement of LVOT gradient before and during verapamil infusion.

Main Results:

  • In a 15-year-old patient, the LVOT gradient decreased from 160 to 45 torr.
  • In a 3-year-old boy, the LVOT gradient reduced from 60 to 10 torr.
  • Significant reduction in LVOT gradient observed in both pediatric cases.

Conclusions:

  • Intravenous verapamil demonstrated effectiveness in reducing LVOT gradients in pediatric HOCM patients.
  • Verapamil may serve as a viable therapeutic option for selected pediatric HOCM cases, especially when other treatments are contraindicated.

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...